STOCKHOLDERS’ EQUITY (Tables)
|
6 Months Ended |
Dec. 31, 2021 |
|---|
| Equity [Abstract] |
|
| SCHEDULE OF STOCK WARRANT ACTIVITY |
Warrant
detail for the six months ended December 31, 2021 is reflected below:
SCHEDULE OF STOCK WARRANT ACTIVITY
| |
|
Number
of Warrants |
|
|
Weighted
Average Exercise Price Per Warrant |
|
|
Remaining
Contract Term (# years) |
|
| Warrants outstanding and exercisable
at June 30, 2021 |
|
|
214,883 |
|
|
$ |
4.49 |
|
|
|
2.92 |
|
| Warrants issued |
|
|
1,071,430 |
|
|
$ |
7.00 |
|
|
|
5.00 |
|
| Warrants outstanding
and exercisable at December 31, 2021 |
|
|
1,286,313 |
|
|
$ |
6.58 |
|
|
|
4.35 |
|
Warrant
detail for the six months ended December 31, 2020 is reflected below:
| |
|
Number
of Warrants |
|
|
Weighted
Average Exercise Price Per Warrant |
|
|
Remaining
Contract Term (# years) |
|
| Warrants outstanding and exercisable
at June 30, 2020 |
|
|
83,205 |
|
|
$ |
4.00 |
|
|
|
2.01 |
|
| Warrants issued |
|
|
185,955 |
|
|
$ |
4.80 |
|
|
|
5.00 |
|
| Warrants outstanding at December 31, 2020 |
|
|
269,160 |
|
|
$ |
4.55 |
|
|
|
3.66 |
|
| Warrants exercisable at December 31, 2020 |
|
|
83,205 |
|
|
$ |
4.00 |
|
|
|
1.50 |
|
|
| SCHEDULE OF STOCK OPTIONS ACTIVITY |
Activity
in the Company’s stock options during the six months ended December 31, 2021 and related balances outstanding as of that date are
reflected below:
SCHEDULE OF STOCK OPTIONS ACTIVITY
| |
|
Number
of Shares |
|
|
Weighted
Average Exercise Price |
|
|
Weighted
Average Remaining Contract Term (#
years)
|
|
| Outstanding at June 30, 2021 |
|
|
531,205 |
|
|
$ |
11.02 |
|
|
|
6.73 |
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
- |
|
| Exercised |
|
|
(3,400 |
) |
|
$ |
4.65 |
|
|
|
- |
|
| Forfeited and cancelled |
|
|
(14,199 |
) |
|
$ |
13.70 |
|
|
|
- |
|
| Outstanding at December 31, 2021 |
|
|
513,606 |
|
|
$ |
10.99 |
|
|
|
6.20 |
|
| Exercisable at December 31, 2021 |
|
|
500,623 |
|
|
$ |
10.95 |
|
|
|
6.16 |
|
Activity
in the Company’s stock options during the six months ended December 31, 2020 and related balances outstanding as of that date are
reflected below:
| |
|
Number
of Shares |
|
|
Weighted
Average Exercise Price |
|
|
Weighted
Average Remaining Contract Term (#
years)
|
|
| Outstanding at June 30, 2020 |
|
|
579,584 |
|
|
$ |
11.00 |
|
|
|
7.55 |
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
- |
|
| Exercised |
|
|
(10,750 |
) |
|
$ |
4.60 |
|
|
|
- |
|
| Forfeited and cancelled |
|
|
(7,463 |
) |
|
$ |
7.31 |
|
|
|
- |
|
| Outstanding at December 31, 2020 |
|
|
561,371 |
|
|
$ |
11.17 |
|
|
|
6.87 |
|
| Exercisable at December 31, 2020 |
|
|
493,224 |
|
|
$ |
10.94 |
|
|
|
6.67 |
|
|
| SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY |
Activity
in RSUs during the six months ended December 31, 2021 and related balances outstanding as of that date are reflected below:
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY
| |
|
Number
of Shares |
|
|
Weighted
Average Grant date Fair Value |
|
|
Weighted
Average Remaining Contract Term (#
years)
|
|
| Outstanding at June 30, 2021 |
|
|
131,652 |
|
|
$ |
9.25 |
|
|
|
2.72 |
|
| Granted |
|
|
179,614 |
|
|
$ |
5.75 |
|
|
|
- |
|
| Forfeited and cancelled |
|
|
(18,334 |
) |
|
$ |
7.71 |
|
|
|
- |
|
| Outstanding at December 31, 2021 |
|
|
292,932 |
|
|
$ |
7.22 |
|
|
|
2.69 |
|
Activity
in RSUs during the six months ended December 31, 2020 and related balances outstanding as of that date are reflected below:
| |
|
Number
of Shares |
|
|
Weighted
Average Grant date Fair Value |
|
|
Weighted
Average Remaining Contract Term (#
years)
|
|
| Outstanding at June 30, 2020 |
|
|
- |
|
|
$ |
- |
|
|
|
- |
|
| Granted |
|
|
134,865 |
|
|
$ |
8.88 |
|
|
|
- |
|
| Forfeited and cancelled |
|
|
(4,228 |
) |
|
$ |
8.88 |
|
|
|
- |
|
| Outstanding at December 31, 2020 |
|
|
130,637 |
|
|
$ |
8.88 |
|
|
|
3.15 |
|
|
| SCHEDULE OF STOCK-BASED COMPENSATION EXPENSES |
The
following table summarizes stock-based compensation expense for employee and non-employee stock option and RSU grants:
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSES
| |
|
Three
Months Ended
December 31,
|
|
|
Six
Months Ended
December 31,
|
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Research and development |
|
$ |
54,000 |
|
|
$ |
45,000 |
|
|
$ |
90,000 |
|
|
$ |
98,000 |
|
| Selling and administrative |
|
|
195,000 |
|
|
|
152,000 |
|
|
|
359,000 |
|
|
|
324,000 |
|
| Total stock-based compensation
expense |
|
$ |
249,000 |
|
|
$ |
197,000 |
|
|
$ |
449,000 |
|
|
$ |
422,000 |
|
|